Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

RCT (n=151) found addition of capivasertib, a pan-AKT inhibitor, to chemotherapy did not extend composite progression-free survival (cPFS) end point in irrespective of PI3K/AKT/PTEN pathway activation status (7.03 vs. 6.70 months, respectively;HR 0.92; 80% CI, 0.73 to 1.16).

Journal of Clinical Oncology